Lilly Looks To Spin Off Animal Health, Focus Cash On Pharma Growth

Lilly confirmed that it will separate its Elanco animal health business from the rest of the company via an IPO, allowing Lilly to focus its resources on pharma growth driven by internal and acquired drugs.